Canjin Halittar Haɗakar EML4-ALK na ɗan adam

Ana amfani da wannan kayan aiki don gano nau'ikan maye gurbi guda 12 na kwayar halittar EML4-ALK a cikin samfuran marasa lafiya da ke fama da cutar kansar huhu ta ɗan adam a cikin vitro. Sakamakon gwajin don amfani ne kawai na asibiti kuma bai kamata a yi amfani da shi azaman tushen magani na musamman ga marasa lafiya ba. Likitoci ya kamata su yanke hukunci mai zurfi kan sakamakon gwajin bisa ga abubuwan da suka shafi yanayin majiyyaci, alamun magani, amsawar magani, da sauran alamun gwajin dakin gwaje-gwaje. Ciwon daji na huhu shine mafi yawan ciwon daji a duniya, kuma kashi 80% ~ 85% na shari'o'in cutar kansar huhu ce da ba ta ƙaramin ƙwayar halitta ba (NSCLC). Haɗakar kwayoyin halitta na echinoderm microtubule-associated protein-like 4 (EML4) da anaplastic lymphoma kinase (ALK) sabon abu ne da aka yi niyya a cikin NSCLC, EML4 da ALK suna cikin mutane bi da bi P21 da P23 akan chromosome 2 kuma an raba su da kusan nau'ikan tushe miliyan 12.7. An gano aƙalla nau'ikan haɗuwa guda 20, daga cikinsu akwai maye gurbi guda 12 da ke cikin Jadawali na 1, inda maye gurbi 1 (E13; A20) ya fi yawa, sai maye gurbi 3a da 3b (E6; A20), wanda ya kai kusan kashi 33% da 29% na marasa lafiya da ke da kwayar halittar EML4-ALK NSCLC, bi da bi. Masu hana ALK da Crizotinib ke wakilta ƙananan ƙwayoyi ne da aka yi niyya ga ƙwayoyin halitta waɗanda aka haɓaka don maye gurbi na haɗin kwayar ALK. Ta hanyar hana ayyukan yankin ALK tyrosine kinase, toshe hanyoyin siginar da ba su dace ba, don haka hana haɓakar ƙwayoyin ciwon daji, don cimma maganin da aka yi niyya ga ciwon daji. Nazarin asibiti ya nuna cewa Crizotinib yana da tasiri fiye da kashi 61% a cikin marasa lafiya da ke da maye gurbi na haɗin EML4-ALK, yayin da kusan ba shi da tasiri ga marasa lafiya na nau'in daji. Saboda haka, gano maye gurbi na haɗin EML4-ALK shine tushen kuma tushen jagorantar amfani da magungunan Crizotinib.